Celsion Corp (CLSN) |
|
1.85 -0.19 (-9.31%)
|
03-05 09:01 |
|
Open: |
2.01 |
Pre. Close: |
2.04 |
|
High:
|
2.01 |
Low:
|
1.62 |
|
Volume:
|
10,553,128 |
Market Cap:
|
135M |
|
|
|
|
Celsion Corporation, an integrated development clinical stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.012 - 2.029 |
2.029 - 2.04 |
|
Low:
|
1.592 - 1.607 |
1.607 - 1.617 |
|
Close:
|
1.828 - 1.854 |
1.854 - 1.872 |
|
Technical analysis |
as of: 2021-03-05 8:44:16 AM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 3.10 One year: 4.06 |
| Support: |
Support1: 1.32 Support2: 1.10 |
| Resistance: |
Resistance1: 2.65 Resistance2: 3.48 |
| Pivot: |
2.19  |
| Moving Average: |
MA(5): 2.05 MA(20): 2.12 
MA(100): 1.03 MA(250): 1.38 |
| MACD: |
MACD(12,26): 0.16 Signal(9): 0.24 |
| Stochastic oscillator: |
%K(14,3): 18.14 %D(3): 21.73 |
| RSI: |
RSI(14): 48.69 |
| 52-week: |
High: 6.50 Low: 0.43 Change(%): 59.5 |
| Average Vol(K): |
3-Month: 1962123 10-Days: 4317464 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.CLSN has closed above bottom band by 14.2%. Bollinger Bands are 88.4% wider than normal. The large width of the bands suggest high volatility as compared to CLSN's normal range. The bands have been in this wide range for 30 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Thu, 25 Feb 2021
Celsion Corporation Provides Clinical Update on Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer Including Encouraging Interim Resection Scores - GlobeNewswire
Mon, 22 Feb 2021
CLSN Stock: Why Biotech Celsion Is Soaring Today - Nasdaq
Mon, 22 Feb 2021
Mid-day market update: Nasdaq tumbles 250 points; Celsion (CLSN Stock) shares spike higher - FXStreet
Mon, 22 Feb 2021
Celsion Corporation Receives FDA Fast Track Designation for GEN-1 in Advanced Ovarian Cancer - GlobeNewswire
Fri, 12 Feb 2021
Thinking about buying stock in Can Fite Biopharma, Celsion Corp, Remark Holdings, Plus Therapeutics, or SenesTech? - PRNewswire
Fri, 12 Feb 2021
Celsion Corporation Announces Formation of Vaccine Advisory Board - GlobeNewswire
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
37 |
| Shares Float (M) |
37 |
|
% Held by Insiders
|
1.25 |
|
% Held by Institutions
|
17.99 |
|
Shares Short (K)
|
1,420 |
|
Shares Short P. Month (K)
|
1,220 |
Stock Financials |
|
EPS
|
-0.747 |
|
EPS Est This Year
|
-3.500 |
|
EPS Est Next Year
|
-1.170 |
|
Book Value (p.s.)
|
0.520 |
|
Profit Margin
|
|
|
Operating Margin
|
-3688.04 |
|
Return on Assets (ttm)
|
-29.6 |
|
Return on Equity (ttm)
|
-126.5 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
-0.336 |
|
Sales Per Share
|
0.013 |
|
EBITDA (p.s.)
|
-0.472 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-18 |
|
Levered Free Cash Flow (M)
|
-12 |
Stock Valuations |
|
PE Ratio
|
-2.48 |
|
PEG Ratio
|
|
|
Price to Book value
|
3.56 |
|
Price to Sales
|
138.45 |
|
Price to Cash Flow
|
-3.96 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
